Shattuck Labs Inc
STTK
View Detailed Chart
3.770USD
+0.200+5.60%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
238.08MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.60%
5 Days
-2.58%
1 Month
-5.28%
6 Months
+360.43%
Year to Date
+3.29%
1 Year
+204.03%
View Detailed Chart
TradingKey Stock Score of Shattuck Labs Inc
Currency: USD Updated: 2026-02-06Key Insights
Shattuck Labs Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.25.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Shattuck Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Shattuck Labs Inc Highlights
StrengthsRisks
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 777.45% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.72M.
Undervalued
The company’s latest PE is -3.81, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 35.95M shares, increasing 10.17% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 216.87K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 6.26.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.250
Target Price
+103.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Shattuck Labs Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Shattuck Labs Inc Info
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Ticker SymbolSTTK
CompanyShattuck Labs Inc
CEOSchreiber (Taylor)
Websitehttps://www.shattucklabs.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68578.000
-1392.130 (-1.99%)
282.580
+22.390 (+8.61%)
2022.560
-29.170 (-1.42%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
